
One of the hottest stocks in 2024 is Humacyte (HUMA), which has surged 163% year-to-date. Valued at $890 million by market cap, Humacyte is engaged in the business of developing and manufacturing implantable, bioengineered human tissues, advanced tissue constructs, and organ systems.
Despite its stellar returns in 2024, Humacyte stock is down 56% from all-time highs, allowing you to buy the dip. Let’s see what’s driving Humacyte stock higher in recent months.